<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31386770</PMID><DateCompleted><Year>2021</Year><Month>06</Month><Day>04</Day></DateCompleted><DateRevised><Year>2021</Year><Month>06</Month><Day>04</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1365-2990</ISSN><JournalIssue CitedMedium="Internet"><Volume>46</Volume><Issue>3</Issue><PubDate><Year>2020</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Neuropathology and applied neurobiology</Title><ISOAbbreviation>Neuropathol Appl Neurobiol</ISOAbbreviation></Journal><ArticleTitle>Neuronal clusterin expression is associated with cognitive protection in amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>255</StartPage><EndPage>263</EndPage><MedlinePgn>255-263</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/nan.12575</ELocationID><Abstract><AbstractText Label="AIMS">Clusterin is a topologically dynamic chaperone protein with the ability to participate in both intra- and extacellular proteostasis. Clusterin has been shown to be upregulated in the spinal cord of patients with amyotrophic lateral sclerosis (ALS) and has been shown to protect against TDP-43 protein misfolding in animal and cell models. Previous studies have demonstrated an association between the pathological burden of TDP-43 misfolding and cognitive deficits in ALS, demonstrating high specificity, but correspondingly low sensitivity owing to a subset of individuals with no evidence of cognitive deficits despite a high burden of TDP-43 pathology, called mismatch cases.</AbstractText><AbstractText Label="METHODS">Hypothesizing that differences in the ability to cope with protein misfolding in these cases may be due to differences in expression of protective mechanisms such as clusterin expression, we assessed the spatial expression of clusterin and another chaperone protein, HspB8, in post mortem brain tissue of mismatch cases. We employed a modified in situ hybridization technique called BaseScope, with single cell, single transcript resolution.</AbstractText><AbstractText Label="RESULTS">Mismatch cases demonstrated differential spatial expression of clusterin, with a predominantly neuronal pattern, compared to cases with cognitive manifestations of their TDP-43 pathology who demonstrated a predominantly glial distribution of expression.</AbstractText><AbstractText Label="CONCLUSIONS">Our data suggest that, in individuals with TDP-43 pathology, predominantly neuronal expression of clusterin in extra-motor brain regions may indicate a cell protective mechanism delaying clinical manifestations such as cognitive dysfunction.</AbstractText><CopyrightInformation>&#xa9; 2019 The Authors. Neuropathology and Applied Neurobiology published by John Wiley &amp; Sons Ltd on behalf of British Neuropathological Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gregory</LastName><ForeName>J M</ForeName><Initials>JM</Initials><Identifier Source="ORCID">0000-0003-3337-4079</Identifier><AffiliationInfo><Affiliation>Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Euan MacDonald Centre for Motor Neurone Disease Research, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Elliott</LastName><ForeName>E</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Euan MacDonald Centre for Motor Neurone Disease Research, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McDade</LastName><ForeName>K</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Euan MacDonald Centre for Motor Neurone Disease Research, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bak</LastName><ForeName>T</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Euan MacDonald Centre for Motor Neurone Disease Research, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Human Cognitive Neuroscience, Psychology, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pal</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Euan MacDonald Centre for Motor Neurone Disease Research, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chandran</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Euan MacDonald Centre for Motor Neurone Disease Research, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abrahams</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Euan MacDonald Centre for Motor Neurone Disease Research, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Human Cognitive Neuroscience, Psychology, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>C</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-4507-5132</Identifier><AffiliationInfo><Affiliation>Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Euan MacDonald Centre for Motor Neurone Disease Research, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>G1100616</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/L023784/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/L023784/2</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/L016400/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>08</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Neuropathol Appl Neurobiol</MedlineTA><NlmUniqueID>7609829</NlmUniqueID><ISSNLinking>0305-1846</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C495242">CLU protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051152">Clusterin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000598624">TARDBP protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051152" MajorTopicYN="N">Clusterin</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="N">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALS</Keyword><Keyword MajorTopicYN="N">ECAS</Keyword><Keyword MajorTopicYN="N">TDP-43</Keyword><Keyword MajorTopicYN="N">cognition</Keyword><Keyword MajorTopicYN="N">neuropathology</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>4</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>7</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>7</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>8</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>6</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>8</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31386770</ArticleId><ArticleId IdType="pmc">PMC7318312</ArticleId><ArticleId IdType="doi">10.1111/nan.12575</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Goldstein LH, Abrahams S. Changes in cognition and behaviour in amyotrophic lateral sclerosis: nature of impairment and implications for assessment. Lancet Neurol 2013; 12: 368&#x2013;80</Citation><ArticleIdList><ArticleId IdType="pubmed">23518330</ArticleId></ArticleIdList></Reference><Reference><Citation>Strong MJ, Abrahams S, Goldstein LH, Woolley S, Mclaughlin P, Snowden J, et al Amyotrophic lateral sclerosis &#x2010; frontotemporal spectrum disorder (ALS&#x2010;FTSD): revised diagnostic criteria. Amyotroph Lateral Scler Frontotemporal Degener 2017; 18: 153&#x2013;174</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7409990</ArticleId><ArticleId IdType="pubmed">28054827</ArticleId></ArticleIdList></Reference><Reference><Citation>Abrahams S, Leigh PN, Harvey A, Vythelingum GN, Gris&#xe9; D, Goldstein LH. Verbal fluency and executive dysfunction in amyotrophic lateral sclerosis (ALS). Neuropsychologia 2000; 38: 734&#x2013;47</Citation><ArticleIdList><ArticleId IdType="pubmed">10689049</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IR, Bigio EH, Ince PG, et al Pathological TDP&#x2010;43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations. Ann Neurol 2007; 61: 427&#x2013;34</Citation><ArticleIdList><ArticleId IdType="pubmed">17469116</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou TT, et al Ubiquitinated TDP&#x2010;43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 2006; 314: 130&#x2013;3</Citation><ArticleIdList><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Buratti E, Baralle FE. The molecular links between TDP&#x2010;43 dysfunction and neurodegeneration. Adv Genet 2009; 66: 1&#x2013;34</Citation><ArticleIdList><ArticleId IdType="pubmed">19737636</ArticleId></ArticleIdList></Reference><Reference><Citation>Abrahams S, Newton J, Niven E, Foley J, Bak TH. Screening for cognition and behaviour changes in ALS. Amyotroph Lat Scler Frontotemp Degener 2014; 15: 9&#x2013;14</Citation><ArticleIdList><ArticleId IdType="pubmed">23781974</ArticleId></ArticleIdList></Reference><Reference><Citation>Niven E, Newton J, Foley J, Colville S, Swingler R, Chandran S, et al Validation of the edinburgh cognitive and behavioural amyotrophic lateral sclerosis screen (ECAS): a cognitive tool for motor disorders. Amyotroph Lat Scler Frontotemp Degener 2015; 16: 172&#x2013;9</Citation><ArticleIdList><ArticleId IdType="pubmed">25967542</ArticleId></ArticleIdList></Reference><Reference><Citation>Siciliano M, Trojano L, Trojsi F, Greco R, Santoro M, Basile G, et al Edinburgh Cognitive and Behavioural ALS Screen (ECAS)&#x2010;Italian version: regression based norms and equivalent scores. Neurol Sci 2017; 38(6): 1059&#x2013;1068.</Citation><ArticleIdList><ArticleId IdType="pubmed">28332040</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye S, Ji Y, Li C, He J, Liu X, Fan D. The Edinburgh cognitive and behavioural ALS screen in a Chinese amyotrophic lateral sclerosis population. PLoS ONE 2016; 11: e0155496</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4873026</ArticleId><ArticleId IdType="pubmed">27195772</ArticleId></ArticleIdList></Reference><Reference><Citation>Loose M, Burkhardt C, Aho&#x2010;&#xd6;zhan H, Keller J, Abdulla S, B&#xf6;hm S, et al Age and education&#x2010;matched cut&#x2010;off scores for the revised German/Swiss&#x2010;German version of ECAS. Amyotroph lateral scler frontotemporal degener 2016; 17: 374&#x2013;6</Citation><ArticleIdList><ArticleId IdType="pubmed">27027323</ArticleId></ArticleIdList></Reference><Reference><Citation>Lul&#xe9; D, Burkhardt C, Abdulla S, B&#xf6;hm S, Kollewe K, Uttner I, et al The Edinburgh cognitive and behavioural amyotrophic lateral sclerosis screen: a cross&#x2010;sectional comparison of established screening tools in a German&#x2010;Swiss population. Amyotroph Lat Scler Frontotemp Degener 2015; 16: 16&#x2013;23</Citation><ArticleIdList><ArticleId IdType="pubmed">25292386</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinto&#x2010;Grau M, Burke T, Lonergan K, McHugh C, Mays I, Madden C, et al Screening for cognitive dysfunction in ALS: validation of the Edinburgh Cognitive and Behavioural ALS Screen (ECAS) using age and education adjusted normative data. Amyotroph Lateral Scler Frontotemporal Degener 2017; 18: 99&#x2013;106</Citation><ArticleIdList><ArticleId IdType="pubmed">27894201</ArticleId></ArticleIdList></Reference><Reference><Citation>Prudlo J, K&#xf6;nig J, Schuster C, Kasper E, B&#xfc;ttner A, Teipel S, et al TDP&#x2010;43 pathology and cognition in ALS: a prospective clinicopathologic correlation study. Neurology 2016; 87: 1019&#x2013;1023</Citation><ArticleIdList><ArticleId IdType="pubmed">27488596</ArticleId></ArticleIdList></Reference><Reference><Citation>Lul&#xe9; D, B&#xf6;hm S, M&#xfc;ller HP, Aho&#x2010;&#xd6;zhan H, Keller J, Gorges M, et al Cognitive phenotypes of sequential staging in amyotrophic lateral sclerosis. Cortex 2018; 101: 163&#x2013;71</Citation><ArticleIdList><ArticleId IdType="pubmed">29477906</ArticleId></ArticleIdList></Reference><Reference><Citation>Gregory JM, Whiten DR, Brown RA, Barros TP, Kumita JR, Yerbury JJ, et al Clusterin protects neurons against intracellular proteotoxicity. Acta Neuropathol Commun 2017; 5: 81</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5678579</ArticleId><ArticleId IdType="pubmed">29115989</ArticleId></ArticleIdList></Reference><Reference><Citation>Gregory JM, Barros TP, Meehan S, Dobson CM, Luheshi LM. The aggregation and neurotoxicity of TDP&#x2010;43 and its ALS&#x2010;associated 25 kDa fragment are differentially affected by molecular chaperones in Drosophila. PLoS ONE 2012; 7: e31899</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3284513</ArticleId><ArticleId IdType="pubmed">22384095</ArticleId></ArticleIdList></Reference><Reference><Citation>Nizard P, Tetley S, Le Drean Y, Watrin T, Le Goff P, Wilson MR, et al Stress&#x2010;induced retrotranslocation of clusterin/ApoJ into the cytosol. Traffic 2007; 8: 544&#x2013;65</Citation><ArticleIdList><ArticleId IdType="pubmed">17451556</ArticleId></ArticleIdList></Reference><Reference><Citation>Crippa V, Cicardi ME, Ramesh N, Seguin SJ, Ganassi M, Bigi I, et al The chaperone HSPB8 reduces the accumulation of truncated TDP&#x2010;43 species in cells and protects against TDP&#x2010;43&#x2010;mediated toxicity. Hum Mol Genet 2016; 25: 3908&#x2013;24</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5291228</ArticleId><ArticleId IdType="pubmed">27466192</ArticleId></ArticleIdList></Reference><Reference><Citation>Cristofani R, Crippa V, Rusmini P, Cicardi ME, Meroni M, Licata NV, et al Inhibition of retrograde transport modulates misfolded protein accumulation and clearance in motoneuron diseases. Autophagy 2017; 13: 1280&#x2013;1303</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5584856</ArticleId><ArticleId IdType="pubmed">28402699</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang F, Flanagan J, Su N, Wang LC, Bui S, Nielson A, et al RNAscope: a novel in situ RNA analysis platform for formalin&#x2010;fixed, paraffin&#x2010;embedded tissues. J Mol Diagn 2012; 14: 22&#x2013;9</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3338343</ArticleId><ArticleId IdType="pubmed">22166544</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattsson N, Insel PS, Donohue M, Landau S, Jagust WJ, Shaw LM, et al; Alzheimer's Disease Neuroimaging Initiative* . Independent information from cerebrospinal fluid amyloid&#x2010;&#x3b2; and florbetapir imaging in Alzheimer's disease. Brain 2015; 138 (Pt 3): 772&#x2013;83</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4339769</ArticleId><ArticleId IdType="pubmed">25541191</ArticleId></ArticleIdList></Reference><Reference><Citation>Forman MS, Schmidt ML, Kasturi S, Perl DP, Lee VM, Trojanowski JQ. Tau and alpha&#x2010;synuclein pathology in amygdala of Parkinsonism&#x2010;dementia complex patients of Guam. Am J Pathol 2002; 160: 1725&#x2013;31</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1850878</ArticleId><ArticleId IdType="pubmed">12000724</ArticleId></ArticleIdList></Reference><Reference><Citation>P&#x159;ikrylov&#xe1; Vranov&#xe1; H, H&#xe9;nykov&#xe1; E, Mare&#x161; J, Kaiserov&#xe1; M, Men&#x161;&#xed;kov&#xe1; K, Va&#x161;t&#xed;k M, et al Clusterin CSF levels in differential diagnosis of neurodegenerative disorders. J Neurol Sci 2016; 361: 117&#x2013;21</Citation><ArticleIdList><ArticleId IdType="pubmed">26810527</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Z, Lee A, Nouwens A, Henderson RD, Mccombe PA. Mass spectrometry analysis of plasma from amyotrophic lateral sclerosis and control subjects. Amyotroph Lateral Scler Frontotemporal Degener 2018; 31: 1&#x2013;15</Citation><ArticleIdList><ArticleId IdType="pubmed">29384411</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>